Vivus VVUS

  1. All
  2. Commentary
  3. Headlines
    1. Orexigen Launches Contrave - Watch For Traction


      Mon, 20 Oct 2014

      Orexigen Launches Contrave - Watch For Traction

    2. Are People Too Concerned About Orexigen's Contrave Label?


      Sun, 19 Oct 2014

      over 10 years. This is following the approval of Belviq (Arena Pharmaceuticals (NASDAQ: ARNA )) and Qsymia ( Vivus (NASDAQ: VVUS )) back in 2012. Following its approval, OREX stock has tanked, dropping nearly 35% from its pre-approval

    3. What To Watch For As Orexigen's Launch Approaches


      Thu, 16 Oct 2014

      denying that Wall Street will be there as well. When launched, Orexigen will join Arena (NASDAQ: ARNA ) and Vivus (NASDAQ: VVUS ) as one of three companies with FDA approved anti-obesity drugs on the market. Other players looking to enter

    4. Orexigen On A Tear - In The Wrong Direction


      Tue, 7 Oct 2014

      potential market to tap into. The real story is that all of the hype and potential of the market size fizzled when Vivus (NASDAQ: VVUS ) launched Qsymia and Arena (NASDAQ: ARNA ) launched Belviq. It was not long after the launch of these drugs

    5. Vivus announces journal publication of Qsymia study results in type 2 diabetes


      Mon, 6 Oct 2014

      A paper examining the results from two studies of Vivus ' (NASDAQ: VVUS ) Qsymia (phentermine and topiramate extended-release) plus lifestyle modification in overweight/obese patients with type

    6. A Look At Arena's Other Drug


      Fri, 3 Oct 2014

      anti-obesity drugs that were being developed simultaneously. Prior to the approval of Arena's Belviq and Vivus Inc.'s (NASDAQ: VVUS ) Qsymia, the FDA had not approved any anti-obesity drug for nearly a decade. The excitement over the

    7. Premature Combination Use Of Belviq And Phentermine Is A Risk


      Sun, 28 Sep 2014

      By Rx Stocks : Obesity drugs, historically, have had poor market success and notable safety issues. Meridia [ Sibutramine ] was withdrawn from the market by Abbott (NYSE: ABT ) because it was associated with an increase in major adverse cardiovascular events [MACE] in the SCOUT trial. The market ...

    8. Belviq Sales Benefit From Advertising - Up 2.8%


      Fri, 26 Sep 2014

      bigger numbers than this), it is positive in that the season is what it is, and the competitor, Qsymia from Vivus (NASDAQ: VVUS ), saw scripts decline by almost 1%. Posting week over week gains at this stage, even if more modest than we

    9. Vivus Up On Erectile Dysfunction Drug - What Should Investors Expect?


      Fri, 19 Sep 2014

      By Spencer Osborne : Vivus (NASDAQ: VVUS ) announced today that the company ..... hour or longer to bring results. Vivus stock soared as high as $4.82 during ..... there. As stated, the label gives Vivus a leg up on the competition in the

    10. It Takes Less Than 15 Minutes To Buy VVUS Shares!


      Fri, 19 Sep 2014

      International (NASDAQ: ENDP ). Vivus Pharmaceuticals (NASDAQ: VVUS ) shares have fallen dramatically ..... What is the revenue potential for VIVUS ? There has been, at times wild ..... Discussion of the earnings potential Vivus ' Complete Story »

    « Prev12345Next »
    Content Partners